L-Tryptophan vs 5-HTP: Serotonin Precursors with Different Safety Profiles

Both L-tryptophan and 5-hydroxytryptophan (5-HTP) are sold as natural mood and sleep aids. Both raise central nervous system serotonin. But the metabolic step that separates them — the activity of tryptophan hydroxylase — matters more than supplement labels suggest, and one of the two has a public-health history that should make any consumer cautious.

The pathway and what each precursor bypasses

Dietary tryptophan competes with other large neutral amino acids for transport across the blood-brain barrier and is then hydroxylated by tryptophan hydroxylase (TPH1 in periphery, TPH2 in brain) to 5-HTP. 5-HTP is then decarboxylated to serotonin (5-HT) by aromatic L-amino acid decarboxylase. Most ingested tryptophan is shunted instead toward the kynurenine pathway via indoleamine 2,3-dioxygenase (IDO), particularly during inflammation. 5-HTP skips both the transport competition and the rate-limiting hydroxylation step, which is why it produces larger increases in central serotonin per milligram dosed.

The 1989 eosinophilia-myalgia syndrome outbreak

In 1989 an outbreak of eosinophilia-myalgia syndrome (EMS) affecting more than 1,500 people and causing at least 37 deaths was traced to L-tryptophan from a single manufacturer (Showa Denko) whose product was contaminated with novel impurities introduced during a manufacturing change [1]. The FDA imposed an import alert in 1990 that effectively removed L-tryptophan from the U.S. market for over a decade. Subsequent pharmaceutical-grade L-tryptophan is considered safe in normal supplemental doses, but the episode remains a textbook case study in supplement-quality risk and is still relevant whenever 5-HTP — which shares biosynthetic origins with tryptophan — is purchased from unknown sources.

Clinical evidence for 5-HTP

The Cochrane review by Shaw and colleagues identified two trials of 5-HTP for depression versus placebo with statistical superiority, though both trials were small and the evidence base was rated insufficient to recommend routine use [2]. Trials for sleep onset latency and for chronic tension headache show modest benefit. Typical doses are 100-300 mg/day in divided doses with food. Carbidopa is sometimes co-administered in research settings to inhibit peripheral decarboxylation and increase central availability; in supplement form, peripheral serotonin production is the main source of gastrointestinal side effects (nausea, loose stool).

Clinical evidence for L-tryptophan

L-tryptophan trials for depression and seasonal affective disorder show modest benefit at doses of 1-3 g/day, and the supplement has been studied as an adjunct to SSRIs in treatment-resistant depression. As a sleep aid it modestly reduces sleep onset latency at 1-2 g taken before bed [3]. The tryptophan depletion paradigm is one of the foundational neuroscience tools for studying acute serotonin reduction effects on mood.

Serotonin syndrome and drug interactions

Both 5-HTP and L-tryptophan can theoretically contribute to serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, tramadol, triptans, linezolid, lithium, or MDMA. Case reports exist but the absolute risk at typical supplement doses combined with one serotonergic agent appears low; combinations with MAOIs are the most dangerous and contraindicated. Anyone taking psychiatric medication should not start either supplement without clinician oversight [4]. Pregnancy use is not recommended due to limited safety data.

Which to choose

5-HTP produces larger central serotonin elevation per milligram and has somewhat more trial support specifically for depression and sleep onset. L-tryptophan has a longer historical use record, broader nutritional role, and a darker manufacturing-contamination episode that left durable regulatory scars. Both are reasonable second-line options for mild mood or sleep symptoms in adults not taking serotonergic medication and not pregnant. Neither is a substitute for evaluation when symptoms are moderate to severe — particularly when treatment-resistant depression is on the table, the right setting is a psychiatry referral, not the supplement aisle.